Brucellosis is an important zoonotic disease with great socio-economic impact in many countries. Infected animals and the resulting contaminated animal products are the main source of human infection. Low degree of protective immunity and serious adverse effects have been reported for both B. abortus vaccine S19 and B. melitensis vaccine Rev.1 vaccines in some vaccination trials. Such variability might be due, at least in part, to the heterogeneity of the vaccines used mainly because of unsuitable quality control during the manufacturing process. So, it is very important to conduct quality tests of vaccine products during the manufacturing of brucellosis vaccines.